• Decoy Therapeutics expects to file a CTA or IND application in the second half of 2027 to begin Phase 1 pan-coronavirus trials.
• An optimized lead candidate showed potential for once-weekly dosing in preclinical studies, compared with daily dosing for earlier candidates.
• Cash totaled $8.1 million at September 30, 2026, including approximately $2.5 million in restricted Gates Foundation grant funding.
• Non-dilutive funding applications and strategic collaborations are being pursued to support development, including an exploratory pan-filovirus program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030715PRIMZONEFULLFEED9868528) on November 03, 2026, and is solely responsible for the information contained therein.